BAD HOMBURG – – November 02, 2026 -- Fresenius has secured exclusive rights to up to 37 biosimilar candidates under a development agreement with WuXi Biologics. The company calls it the largest development agreement announced in the biosimilars industry to date. The deal could lift Fresenius' portfolio from 29 marketed and pipeline molecules today to as many as 66 over the next decade, addressing more than €370 billion in originator list-price-based sales.

Madrid – October 01, 2026 -- Fresenius SE & Co. KGaA has completed the acquisition of the remaining 45% stake in mAbxience from Insud Pharma, giving the German healthcare group full ownership of the Spanish biosimilars manufacturer.

Madrid – September 19, 2026 -- mAbxience and Sandoz have signed a licensing, development, manufacturing and commercialization agreement for a proposed emicizumab biosimilar targeting hemophilia A, a treatment referencing Roche's Hemlibra with an estimated global reference market of USD 5.7 billion.